Gunma Institute for Allergy and Asthma, Gunma Hospital for Allergic and Respiratory Diseases, Gunma, Japan.
Int Arch Allergy Immunol. 2011;156(4):405-11. doi: 10.1159/000324463. Epub 2011 Aug 9.
There has been no report that investigated β(2)-adrenergic receptor (ADRB2) gene polymorphism in patients with aspirin-exacerbated respiratory disease (AERD).
DNA in the specimens in three groups of study subjects classified patients with AERD, patients with aspirin-tolerant asthma (ATA) and normal controls was extracted, and the target DNA sequence of the ADRB2 was amplified using a set of primers to generate an amplicon of 219 bp in length. Allelic discrimination assay for single nucleotide polymorphisms relating to the ADRB2 gene expression was carried out by using a previously described single nucleotide polymorphism detective system, sequence-specific thermal-elution chromatography.
The frequency of the Gly variant allele in patients with AERD was significantly lower than that in patients with ATA (p = 0.007), and the odds ratio (OR) of AERD to ATA associated with wild-type ArgArg homozygote was 3.300. Frequencies of wild-type ArgArg homozygote are significantly higher than those of variant-type ArgGly/GlyGly genotype in patients with AERD compared with those with ATA (p < 0.001, OR = 3.153). In patients with AERD, frequencies of wild-type ArgArg homozygote in both female and male patients are significantly higher than those of variant-type ArgGly/GlyGly genotype in male patients compared with those with ATA (p < 0.001, OR = 5.128 and p = 0.007, OR = 4.367, respectively). Also, in patients with AERD, frequencies of wild-type ArgArg homozygote in female patients are significantly higher than those of variant-type ArgGly/GlyGly genotype in female patients compared with those with ATA (p = 0.002, OR = 2.825).
We were the first to analyze Arg16Gly ADRB2 gene polymorphism in Japanese patients with AERD, and showed that Arg16Gly ADRB2 gene polymorphism in Japanese patients with AERD is different from that in the patients with ATA.
目前尚无研究报道β(2)-肾上腺素能受体(ADRB2)基因多态性与阿司匹林加重性呼吸系统疾病(AERD)之间的关系。
提取三组研究对象的标本中的 DNA,将 AERD 患者、阿司匹林耐受型哮喘(ATA)患者和正常对照者分类,采用一套引物扩增 ADRB2 的靶 DNA 序列,产生 219bp 长的扩增子。采用先前描述的单核苷酸多态性检测系统——序列特异性热洗脱色谱法,对与 ADRB2 基因表达相关的单核苷酸多态性进行等位基因鉴别分析。
AERD 患者 Gly 变异等位基因的频率明显低于 ATA 患者(p=0.007),与野生型 ArgArg 纯合子相关的 AERD 对 ATA 的比值比(OR)为 3.300。AERD 患者中野生型 ArgArg 纯合子的频率明显高于 ATA 患者的变异型 ArgGly/GlyGly 基因型(p<0.001,OR=3.153)。在 AERD 患者中,无论男女,野生型 ArgArg 纯合子的频率均明显高于 ATA 患者的变异型 ArgGly/GlyGly 基因型(p<0.001,OR=5.128 和 p=0.007,OR=4.367)。此外,在 AERD 患者中,女性患者野生型 ArgArg 纯合子的频率明显高于 ATA 患者的变异型 ArgGly/GlyGly 基因型(p=0.002,OR=2.825)。
我们首次分析了日本 AERD 患者的 Arg16Gly ADRB2 基因多态性,结果显示日本 AERD 患者的 Arg16Gly ADRB2 基因多态性与 ATA 患者不同。